Genmab Business Model Canvas: Complete BMC Analysis
The Genmab Business Model Canvas reveals how Denmark's most valuable biotech company has built a unique antibody innovation engine that generates DKK 20 billion+ in annual revenue. With Darzalex (daratumumab — partnered with J&J) generating $10B+ as the world's best-selling multiple myeloma drug, Genmab combines proprietary antibody technology platforms (DuoBody, HexaBody, DuoHexaBody) with strategic partnerships to create differentiated cancer therapeutics.
Value Propositions in Genmab's BMC
Genmab's Value Propositions include proprietary antibody technology platforms (DuoBody bispecific, HexaBody complement, DuoHexaBody), blockbuster partnered products (Darzalex — J&J, Kesimpta — Novartis, Tepkinly — AbbVie), a deep pipeline of next-generation antibody therapeutics, and fast-follower/best-in-class positioning. This technology-platform biotech model contrasts with the large-pharma R&D approach of the Novo Nordisk Business Model Canvas and the enzyme biotech model of the Novozymes Business Model Canvas.
Customer Segments and Revenue Streams
Genmab's Customer Segments include pharma partners (J&J, AbbVie, Novartis, BioNTech), oncologists & hematologists (indirect — via partners), hospitals & cancer centers, regulatory agencies, and patient advocacy groups. Revenue Streams derive from royalties on partnered products (Darzalex, Kesimpta, Tepkinly), milestone payments, co-promotion revenue, and proprietary product sales.
Key Partners and Key Resources
The Key Partners block includes Johnson & Johnson (Darzalex — daratumumab), AbbVie (Tepkinly — epcoritamab), Novartis (Kesimpta — ofatumumab), BioNTech (bispecific antibodies), CROs (clinical trial execution), and CMOs (manufacturing). Key Resources encompass DuoBody, HexaBody & DuoHexaBody platforms, antibody IP & patents, 1,800+ employees, clinical pipeline (20+ programs), and scientific advisory board.
Key Activities and Cost Structure
Genmab's Key Activities include antibody discovery & engineering, clinical development, partnership management, regulatory strategy, and proprietary product commercialization. The Cost Structure covers R&D investment (60%+ of expenses), clinical trial costs, employee compensation, partnership management, and regulatory submissions. This R&D-heavy biotech model parallels the innovation investment in the Novozymes Business Model Canvas.
Channels and Customer Relationships
Genmab's Channels include partnered commercial infrastructure (J&J, AbbVie sales forces), direct commercialization (proprietary products), scientific conferences, medical affairs teams, and publication strategy. Customer Relationships leverage deep partner collaboration, KOL engagement, clinical investigator networks, and patient advocacy partnerships.
Comparing Biotech Business Model Canvases
Study related BMC examples: the Novo Nordisk BMC for Danish pharma scale, Novozymes BMC for Danish industrial biotech, Coloplast BMC for Danish medtech, the Ambu BMC for Danish healthcare devices, the Roche BMC for oncology focus, and the Johnson & Johnson BMC for diversified pharma. Each Business Model Canvas shows how life-science companies monetize innovation.